Gene · 23765
Papers3,930
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 3,930
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
Multiscale computational elucidation of Interleukin-17 receptor A-E3 ubiquitin ligase TRAF3IP2 signaling nexus: structural dynamics and hotspots for targeted autoimmune and anti-inflammatory therapeutics. | Int J Biol Macromol | 2025 | 41067334 | PubTator, text mining | PubMed |
| Emodin Alleviates Monocrotaline-Induced Pulmonary Arterial Hypertension by Directly Targeting TAK1. | Drug Des Devel Ther | 2025 | 41049040 | PubTator, text mining | PubMed |
| 4-1BB+ Tregs and inhibitory progenitor exhausted T cells confer resistance to anti-PD-L1 and anti-CTLA-4 combination therapy. | Cell Rep Med | 2025 | 41045934 | PubTator, text mining | PubMed |
| Interleukin-17 receptor-A signalling: atheroprotective role in JAK2 clonal haematopoiesis. | Eur Heart J | 2025 | 40986427 | PubTator, text mining | PubMed |
| Long Non-Coding RNAs in Psoriasis: A Comprehensive Review of Expression Profiles, Mechanistic Insights, Genetic Associations, and Their Clinical Implications. | Noncoding RNA | 2025 | 40981386 | PubTator, text mining | PubMed |
| IL17RA and IL21R polymorphisms influence type 1 diabetes predisposition and autoimmune phenotypes. | Front Endocrinol (Lausanne) | 2025 | 40979706 | PubTator, text mining | PubMed |
| Brodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure. | Dermatol Ther (Heidelb) | 2025 | 40971026 | PubTator, text mining | PubMed |
| Orismilast, a Potent and Selective PDE4B/D Inhibitor, Reduces Protein Levels of Key Disease Driving Cytokines in the Skin of Patients With Plaque Psoriasis. | Exp Dermatol | 2025 | 40970551 | PubTator, text mining | PubMed |
| Integrated Single-Cell and Spatial Transcriptomic Analysis Reveals a Pathological Niche Formed by FAP+ Fibroblasts, Immune, and Endothelial Cells in Psoriatic Lesions. | Clin Cosmet Investig Dermatol | 2025 | 40963886 | PubTator, text mining | PubMed |
| Niraparib Demonstrates Therapeutic Potential in Multiple Sclerosis through Inhibition of IL-17A Receptor Interaction and Promotion of Remyelination. | ACS Chem Neurosci | 2025 | 40924614 | PubTator, text mining | PubMed |
| HIV-1 manipulates CD96 on CD4+ T cells to subvert antiviral immunity. | Sci Adv | 2025 | 40911682 | PubTator, text mining | PubMed |
| Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events. | JAMA Dermatol | 2025 | 40900466 | PubTator, text mining | PubMed |
| Target discovery-directed pharmacological mechanism elucidation of bioactive natural products. | Med Rev (2021) | 2025 | 40838108 | PubTator, text mining | PubMed |
| Taurochenodeoxycholic acid as a sensitive stratification marker for HBV-associated hepatic cirrhosis status has a hepatoprotective effect. | Sci Rep | 2025 | 40835888 | PubTator, text mining | PubMed |
| HPV16 E6 and E7 expressing cancer cells suppress the antitumor immune response by upregulating KLF2-mediated IL-23 expression in macrophages. | J Immunother Cancer | 2025 | 40829900 | PubTator, text mining | PubMed |
| IL-17 Stimulates Sensory Neurons and Sensitises Colonic Afferents to Noxious Stimuli in a PI3K Dependent Manner in Male Mice. | J Neurochem | 2025 | 40827457 | PubTator, text mining | PubMed |
| Adverse Events and Immune Response in Psoriasis Patients Receiving Interleukin-17 Inhibitors. | Acta Derm Venereol | 2025 | 40824162 | PubTator, text mining | PubMed |
| Identification of an IL17RC missense variant in a Chinese family with multiple osteochondromas and ankylosing spondylitis. | J Hum Genet | 2025 | 40813448 | PubTator, text mining | PubMed |
| A Common Genetic Background for Psoriasis and Cardiovascular Diseases: A Narrative Review. | Health Sci Rep | 2025 | 40809699 | PubTator, text mining | PubMed |
| Identifying inflammatory bowel disease subtypes: a comprehensive exploration of transcriptomic data and machine learning-based approaches. | Ther Adv Gastroenterol | 2025 | 40808866 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/23765/papers?page=7